Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Jan 8

PMID 31906235

Citations 16

Authors

Maria Mrakovcic

Leopold F Frohlich

Affiliations

Soon will be listed here.

Abstract

Histone deacetylation inhibitors (HDACi) offer high potential for future cancer therapy as they can re-establish the expression of epigenetically silenced cell death programs. HDACi-induced autophagy offers the possibility to counteract the frequently present apoptosis-resistance as well as stress conditions of cancer cells. Opposed to the function of apoptosis and necrosis however, autophagy activated in cancer cells can engage in a tumor-suppressive or tumor-promoting manner depending on mostly unclarified factors. As a physiological adaption to apoptosis resistance in early phases of tumorigenesis, autophagy seems to resume a tumorsuppressive role that confines tumor necrosis and inflammation or even induces cell death in malignant cells. During later stages of tumor development, chemotherapeutic drug-induced autophagy seems to be reprogrammed by the cancer cell to prevent its elimination and support tumor progression. Consistently, HDACi-mediated activation of autophagy seems to exert a protective function that prevents the induction of apoptotic or necrotic cell death in cancer cells. Thus, resistance to HDACi-induced cell death is often encountered in various types of cancer as well. The current review highlights the different mechanisms of HDACi-elicited autophagy and corresponding possible molecular determinants of therapeutic resistance in cancer.

Citing Articles

Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat.

El Omari N, Khalid A, Makeen H, Alhazmi H, Albratty M, Mohan S Heliyon. 2024; 10(12):e33052.

PMID: 39021957 PMC: 11253278. DOI: 10.1016/j.heliyon.2024.e33052.

The dual role of autophagy in the regulation of cancer treatment.

Kwantwi L Amino Acids. 2024; 56(1):7.

PMID: 38310598 PMC: 10838838. DOI: 10.1007/s00726-023-03364-4.

Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells.

Zichittella C, Loria M, Celesia A, Di Liberto D, Corrado C, Alessandro R Front Pharmacol. 2023; 14:1275833.

PMID: 37841928 PMC: 10572549. DOI: 10.3389/fphar.2023.1275833.

Dysregulation of Histone Deacetylases Inhibits Trophoblast Growth during Early Placental Development Partially through TFEB-Dependent Autophagy-Lysosomal Pathway.

Wang P, Zhao C, Zhou H, Huang X, Ying H, Zhang S Int J Mol Sci. 2023; 24(15).

PMID: 37569278 PMC: 10418899. DOI: 10.3390/ijms241511899.

Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells.

Fischer M, Mustafa A, Hausmann K, Ashry R, Kansy A, Liebl M J Adv Res. 2023; 60:201-214.

PMID: 37467961 PMC: 11156613. DOI: 10.1016/j.jare.2023.07.005.

References

Kim M, Kwon H, Lee Y, Baek J, Jang J, Lee S . Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7(4):437-43. DOI: 10.1038/86507. View

Spange S, Wagner T, Heinzel T, Kramer O . Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol. 2008; 41(1):185-98. DOI: 10.1016/j.biocel.2008.08.027. View

Di Giacomo V, Di Valerio V, Rapino M, Bosco D, Cacciatore I, Ciulla M . MRJF4, a novel histone deacetylase inhibitor, induces p21 mediated autophagy in PC3 prostate cancer cells. Cell Mol Biol (Noisy-le-grand). 2015; 61(3):17-23. View

Duprez L, Wirawan E, Vanden Berghe T, Vandenabeele P . Major cell death pathways at a glance. Microbes Infect. 2009; 11(13):1050-62. DOI: 10.1016/j.micinf.2009.08.013. View

Robey R, Chakraborty A, Basseville A, Luchenko V, Bahr J, Zhan Z . Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm. 2011; 8(6):2021-31. PMC: 3230675. DOI: 10.1021/mp200329f. View

Mrakovcic M, Bohner L, Hanisch M, Frohlich L . Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53. Int J Mol Sci. 2018; 19(12). PMC: 6321134. DOI: 10.3390/ijms19123952. View

He C, Levine B . The Beclin 1 interactome. Curr Opin Cell Biol. 2010; 22(2):140-9. PMC: 2854269. DOI: 10.1016/j.ceb.2010.01.001. View

Vrana J, DECKER R, Johnson C, Wang Z, Jarvis W, Richon V . Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene. 1999; 18(50):7016-25. DOI: 10.1038/sj.onc.1203176. View

Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F . Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005; 280(29):26729-34. DOI: 10.1074/jbc.C500186200. View

10.

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

11.

De U, Son J, Sachan R, Park Y, Kang D, Yoon K . A New Synthetic Histone Deacetylase Inhibitor, MHY2256, Induces Apoptosis and Autophagy Cell Death in Endometrial Cancer Cells via p53 Acetylation. Int J Mol Sci. 2018; 19(9). PMC: 6164480. DOI: 10.3390/ijms19092743. View

12.

Taguchi K, Fujikawa N, Komatsu M, Ishii T, Unno M, Akaike T . Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc Natl Acad Sci U S A. 2012; 109(34):13561-6. PMC: 3427110. DOI: 10.1073/pnas.1121572109. View

13.

Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X . Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene. 2012; 32(5):599-609. PMC: 3371110. DOI: 10.1038/onc.2012.81. View

14.

Bao L, Jaramillo M, Zhang Z, Zheng Y, Yao M, Zhang D . Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol. 2014; 7(4):1502-13. PMC: 4014230. View

15.

Lee D, HAYES J, Pruss D, Wolffe A . A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell. 1993; 72(1):73-84. DOI: 10.1016/0092-8674(93)90051-q. View

16.

Feng Z . p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol. 2010; 2(2):a001057. PMC: 2828273. DOI: 10.1101/cshperspect.a001057. View

17.

Lu M, Ji J, Jiang Z, You Q . The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Med Res Rev. 2016; 36(5):924-63. DOI: 10.1002/med.21396. View

18.

Rikiishi H . Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol. 2011; 2011:830260. PMC: 3100649. DOI: 10.1155/2011/830260. View

19.

Yamamoto M, Kensler T, Motohashi H . The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev. 2018; 98(3):1169-1203. PMC: 9762786. DOI: 10.1152/physrev.00023.2017. View

20.

Kaushik S, Cuervo A . Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol. 2012; 22(8):407-17. PMC: 3408550. DOI: 10.1016/j.tcb.2012.05.006. View